

2.5.7 REFERENCES

1. Abraham P, Avenell A, Park CM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. *Eur J Endocrinol* 2005; 153(4):489-98.
2. Acker CG, Singh AR, Flick RP, et al. A trial of thyroxine in acute renal failure. *Kidney Int* 2000; 57(1):293-8.
3. Actavis-UK. Summary of Product Characteristics: Levothyroxine tablets BP 50 micrograms [Internet]. Barnstaple (UK): Actavis UK Limited; 2014 Jul 21 [cited 2017 Aug 15]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=23994>
4. Adrees M, Gibney J, El-Saeity N, et al. Effects of 18 months of L-T4 replacement in women with subclinical hypothyroidism. *Clin Endocrinol* 2009; 71(2):298-303.
5. Agrawal P, Philip R, Saran S, et al. Congenital hypothyroidism. *Indian J Endocrinol Metab* 2015; 19(2):221-7.
6. AHFS (American Hospital Formulary Service) - Drug information. Levothyroxine sodium / Thyroid agents general statement [Internet]. Stuttgart (DE): Wissenschaftliche Verlagsgesellschaft; 2017 [cited 2017 Aug 09]. Available from: <http://www.drugbase.de>
7. AIFA (Agenzia Italiana del Farmaco). L'uso dei farmaci in Italia. Rapporto nazionale anno 2016 [cited 2017 Nov 07]. Available from: <http://www.aifa.gov.it/content/luso-dei-farmaci-italia-rapporto-osmed-2016>
8. Aksoy DY, Kerimoglu U, Okur H, et al. Effects of prophylactic thyroid hormone replacement in euthyroid Hashimoto's thyroiditis. *Endocr J* 2005; 52(3):337-43.
9. Albert BB, Heather N, Derraik JG, et al. Neurodevelopmental and body composition outcomes in children with congenital hypothyroidism treated with high-dose initial replacement and close monitoring. *J Clin Endocrinol Metab* 2013; 98(9):3663-70.
10. Alevizaki M, Mantzou E, Cimponeriu AT, et al. TSH may not be a good marker for adequate thyroid hormone replacement therapy. *Wien Klin Wochenschr* 2005; 117(18):636-40.
11. Al-Numani D, Scarsi C, Ducharme MP. Levothyroxine soft capsules demonstrate bioequivalent pharmacokinetic exposure with the European reference tablets in healthy volunteers under fasting conditions. *Int J Clin Pharmacol Ther* 2016; 54(2):135-43.
12. Ananthakrishnan S, Braverman LE, Levin RM, et al. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. *Thyroid* 2008; 18(5):493-8.
13. Anderson L, Joseph F, Goenka N, et al. Isolated thyroxine malabsorption treated with intramuscular thyroxine injections. *Am J Med Sci* 2009; 337(2):150-2.
14. Anderson PE, Hurley PR, Rosswick P. Conservative treatment and long term prophylactic thyroxine in the prevention of recurrence of multinodular goitre. *Surg Gynecol Obstet* 1990; 171:309-14.
15. ANSM. Database search (L'Agence nationale de sécurité du médicament et des produits de santé) for registration of medicinal products containing levothyroxine as active pharmaceutical ingredient. 2017 [cited 2017 Nov 02]. Available from: <http://www.ansm.sante.fr/searchengine/search?keyword=>
16. Arem R, Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. *Arch Intern Med* 1990; 150:2097-100.
17. Aristo Pharma-DE. Fachinformation (SPC): Eferox® Loesung zum Einnehmen [Internet]. Berlin (DE): Aristo Pharma GmbH; April 2016 [cited 2017 Aug 01]. Available from: <http://fachinformation.srz.de/pdf/aristo/eferoxl%C3%B6sung.pdf>

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

18. Ashley WW Jr, Ojemann JG, Park TS, et al. Primary hypothyroidism in a 12-year-old girl with a suprasellar pituitary mass: rapid regression after thyroid replacement therapy: case report. *J Neurosurg* 2005; 102 Suppl 4:413-6.
19. Aydin A, Cemeroglu AP, Baklan B. Thyroxine-induced hypermotor seizure. *Seizure* 2004; 13(1):61-5.
20. Bach-Huynh TG, Jonklaas J. Thyroid medications during pregnancy. *Ther Drug Monit* 2006; 28(3):431-41.
21. Baldini M, Gallazzi M, Orsatti A, et al. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. *J Intern Med* 2002; 251(5):407-14.
22. Bartalena L, Martino E, Pacchiarotti A, et al. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. *J Clin Endocrinol Metab* 1987; 64:849-55.
23. Bauer M, Hellweg R, Baumgartner A. Hochdosierte Thyroxinbehandlung bei therapie- und prophylaxeresistenten Patienten mit affektiven Psychosen. High dosage thyroxine treatment in therapy and prevention refractory patients with affective psychoses. *Nervenarzt* 1998; 69(11):1019-22.
24. Bauer M, Priebe S, Berghoefler A, et al. Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders. *J Affect Disord* 2001; 64(1):35-42.
25. Bell GM, Todd WT, Forfar JC, et al. End-organ responses to throxine therapy in subclinical hypothyroidism. *Clin Endocrinol* 1985; 22:83-9.
26. Ben-Skowronek I, Wisniowiecka M. Replacement therapy of secondary hypothyroidism in children born with low body weight improves mental development. *Ann Agric Environ Med* 2012; 19(3):567-71.
27. Berghout A, Wiersinga WM, Drexhage H, et al. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. *Lancet* 1990; 336:193-7.
28. BfArM (Bundesinstitut fuer Arzneimittel und Medizinprodukte). Fixe AM-Kombination von Levothyroxin und Liothyronin (Tabletten 25 µg + 5 µg / 100 µg + 20 µg). Mustertext zur Fachinformation fi3800ap (levothyroxin+_oral_spdcde_1999-05-20_004). Date: 20 May 1999.
29. BfArM (Bundesinstitut fuer Arzneimittel und Medizinprodukte). Levothyroxin-Natrium. Mustertexte zur Fachinformation levothyroxin_oral_spdcde_2002-11-05_003 und zur Gebrauchsinformation levothyroxin_oral_pal_2002-11-05_004. Date: 05 Nov 2002.
30. BfArM (Bundesinstitut fuer Arzneimittel und Medizinprodukte). Public assessment report: Tirosint 13, 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200 micrograms soft capsules. Levothyroxine sodium. Procedure number DE/H/2580/01-12/DC [Internet]. Loerrach (DE): Regiomedica GmbH; 20 Mar 2011 [cited 2017 Aug 01]. Available from: https://mri.cts-mrp.eu/Human/Downloads/DE_H_2580_012_PAR.pdf
31. BfArM-AMIS (Bundesinstitut fuer Arzneimittel und Medizinprodukte, Arzneimittelinformationssystem). Tirosint Weichkapseln (registered preparations in Germany) [Internet]. 01.08.2017a [cited 2017 Aug 02]. Available from: https://portal.dimdi.de/websearch/servlet/FlowController/AcceptFZK#_DEFANCHOR__
32. BfArM-AMIS (Bundesinstitut fuer Arzneimittel und Medizinprodukte, Arzneimittelinformationssystem). (((Stoffname: (LEVOTHYROXIN?; LEVOTHYROXIN-NATRIUM?) UND Arzneilich wirksame Bestandteile)/SAME STF) UND Anzahl Wirkstoffe: 01) UND Nur verkehrsfähige Arzneimittel UND Nur Humanarzneimittel (registered preparations in Germany) [Internet]. 11.10.2017b [cited 2017 Oct 11]. Available from: https://portal.dimdi.de/websearch/servlet/FlowController/AcceptFZK#_DEFANCHOR__

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

33. BGP Pharma-CA. Product Monograph: Synthroid® levothyroxine sodium tablets, USP 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg (Submission Control No: 181937). Montreal (CA): BGP Pharma ULC; 2015 Aug 20.
34. Bhargav PR, Mishra A, Agarwal G, et al. Prevalence of hypothyroidism in benign breast disorders and effect of thyroxine replacement on the clinical outcome. *World J Surg* 2009; 33(10):2087-93.
35. Binimelis J, Bassas L, Marruecos L, et al. Massive thyroxine intoxication: evaluation of plasma extraction. *Intensive Care Med* 1987; 13:33-8.
36. Blackburn S. Maternal-fetal thyroid interactions. *J Perinat Neonatal Nurs* 2009; 23(4):312-3.
37. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. *J Clin Endocrinol Metab* 2010;95:2715–26.
38. Boerner W. Schilddruesenhormone - Thyreostatika. *Med Klin* 1974; 69:1407-16.
39. Bogazzi F, Bartalena L, Brogioni S, et al. L-thyroxine directly affects expression of thyroid hormone-sensitive genes: regulatory effect of RXRβ. *Mol Cell Endocrinol* 1997; 134(1):23-31.
40. Briet JM, Van Wassenaer AG, Van Baar A, et al. Evaluation of the effect of thyroxine supplementation on behavioural outcome in very preterm infants. *Dev Med Child Neurol* 1999; 41(2):87-93.
41. Briggs GG, Freeman RK, Yaffe SJ, editors. *Drugs in pregnancy and lactation - A reference guide to fetal and neonatal risk. Levothyroxine*. 9th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2011. p. 829-31.
42. Bueyuekgebiz A. Newborn screening for congenital hypothyroidism. *J Clin Res Pediatr Endocrinol* 2013; 5 Suppl 1:8-12.
43. Burger, AG. Neue Aspekte der peripheren Wirkung der Schilddrüsenhormone. *Triangel* 1983; 22:175-9.
44. Burmeister LA, Goumaz MO, Mariash CN, et al. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. *J Clin Endocrinol Metab* 1992; 75:344-50.
45. Cady B, Cohn K, Rossi RL, et al. The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. *Surgery* 1983; 94:978-83.
46. Canbay A, Gieseler R, Ella R, et al. Manifestation einer Nebennierenrindeninsuffizienz nach Gabe von Levothyroxin bei einem Patienten mit polyglandulaerem Autoimmunsyndrom Type II (Schmidt-Syndrom). *Internist (Berl)* 2000; 41(6):588-91.
47. Caron P, Calazel C, Parra HJ, et al. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy. *Clin Endocrinol* 1990; 33:519-23.
48. Carswell JM, Gordon JH, Popovsky E, et al. Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism. *J Clin Endocrinol Metab* 2013; 98(2):610-7.
49. Cassio A, Monti S, Rizzello A, et al. Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. *J Pediatr* 2013; 162(6):1264-9, 1269.e1-2.
50. Catli G, Anik A, Tuhan HU, et al. The effect of L-thyroxine treatment on hypothyroid symptom scores and lipid profile in children with subclinical hypothyroidism. *J Clin Res Pediatr Endocrinol* 2014; 6(4):238-44.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

51. CBG-MEB (College ter Beoordeling van Geneesmiddelen-Medicines Evaluation Board, Netherlands). Eltroxin, Euthyrox. Database human medicines. Available from: http://www.cbg-meb.nl/CBG/en/_search/searchresult/default.htm?qry=euthyrox&language=en; downloaded October 10 2017.
52. Celani MF, Mariani M, Mariani G. On the usefulness of levothyroxine suppressive therapy in the medical treatment of benign solitary, solid or predominantly solid, thyroid nodules. *Acta Endocrinol* 1990; 123:603-8.
53. Centanni M, Franchi A, Santaguida MG, et al. La terapia tiroxinica: dall'empirismo al dosaggio individualizzato [Oral thyroxine treatment: towards an individually tailored dose]. *Recenti Prog Med* 2007; 98(9):445-51.
54. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, *Helicobacter pylori* infection, and chronic gastritis. *N Engl J Med* 2006; 354:1787-95.
55. Cesareo R, Iozzino M, Isgro MA, et al. Short term effects of levothyroxine treatment in thyroid multinodular disease. *Endocr J* 2010; 57(9):803-9.
56. Chao M, Jiawei X, Xia H, et al. Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. *Nucl Med Commun* 2009; 30:586-93.
57. Chelimsky G, Davis ID, Kliegman RM. Neonatal hyponatremia associated with congenital hypothyroidism. *Clin Pediatr (Phila)* 1997; 36(3):177-80.
58. Chen YC, Fang JT, Chang CT, et al. Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction. *Ren Fail* 2001; 23(1):139-42.
59. Cheung PS, Lee JM, Boey JH. Thyroxine suppressive therapy of benign solitary thyroid nodules: a prospective randomized study. *World J Surg* 1989; 13:818-22.
60. Choi YH, Choi WY, Kang HC, Koh YI, Bae EH, Kim SW. Drug Rash Induced by Levothyroxine Tablets. *Thyroid*. October 2012, 22(10): 1090-1090.
61. Cholongitas E, Georgousaki C, Spyrou S, et al. Stevens-Johnson syndrome related to ciprofloxacin, possibly enhanced by overadministration of levothyroxine. *Dermatol Online J* 2009; 15(11):16.
62. Chopra IJ, Baber K. Treatment of primary hypothyroidism during pregnancy: is there an increase in thyroxine dose requirement in pregnancy? *Metabolism* 2003; 52(1):122-8.
63. Choudhary N, Chikkaveerappa K, Underwood P, Leong KS. Thyroxine replacement precipitating adrenal crisis. *Endocrine abstracts* 2009 (19), p64.
64. Christensen-Adad FC, Mendes-Dos-Santos CT, Goto MM, et al. Neonatal screening: 9% of children with filter-paper blood-spot TSH levels between 5 and 10µIU/mL have congenital hypothyroidism. *J Pediatr (Rio J)* 2017 Jul 21.
65. Cinemre H, Bilir C, Gokosmanoglu F, et al. Hematologic effects of levothyroxine in iron-deficient subclinical hypothyroid patients: a randomized, double-blind, controlled study. *J Clin Endocrinol Metab* 2009; 94(1):151-6.
66. Cohen JH, Ingbar SH, Braverman LE. Thyrotoxicosis due to ingestion of excess thyroid hormone. *Endocr Rev* 1989; 10:113-24.
67. Colonis Pharma-UK. Summary of Product Characteristics: Levothyroxine 25 micrograms/5ml oral solution [Internet]. Burnopfield (UK): Colonis Pharma Ltd; 2017 May 13 [cited 2017 Aug 01]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=33293>
68. Colucci P, D'Angelo P, Mautone G, et al. Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. *Ther Drug Monit* 2011; 33(3):355-61.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

69. Connelly TJ, El-Hayek R, Sukhareva M, et al. L-thyroxine activates the intracellular Ca²⁺ release channel of skeletal muscle sarcoplasmic reticulum. *Biochem Mol Biol Int* 1994; 32(3):441-448.
70. Cooper DS, Halpern R, Wood LC, et al. L-thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. *Ann Intern Med* 1984; 101:18-24.
71. Cooper JG, Harboe K, Frost SK, et al. Ciprofloxacin interacts with thyroid replacement therapy. *BMJ* 2005; 330(7498):1002.
72. Corrias A, Mussa A, Wasniewska M, et al. Levothyroxine treatment in pediatric benign thyroid nodules. *Horm Res Paediatr* 2011; 75(4):246-51.
73. Corriveau S, Pasquier JC, Blouin S, et al. Chronic levothyroxine and acute T3 treatments enhance the amplitude and time course of uterine contractions in human. *Am J Physiol Endocrinol Metab* 2013; 304(5):E478-85.
74. Crow S, Mitchell J, Kendall D. Levotyroxine abuse and bulimia nervosa. *Psychosomatics*, 1997; 38(2):151-153
75. CVMP (Committee for Veterinary Medicinal Products). Summary report: Levothyroxine (EMA/MRL/319/97-FINAL) [Internet]. London: The European Agency for the Evaluation of Medicinal Products - Veterinary Medicines Evaluation Unit; 1998 June. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_Report/2009/11/WC500014686.pdf
76. Danese MD, Ladenson PW, Meinert CL, et al. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. *J Clin Endocrinol Metab* 2000; 85(9):2993-3001.
77. De Groot L, Abalovich M, Alexander EK, et al. The Endocrine Society's clinical guidelines. Executive summary. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2012; 97:2543-65.
78. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. *Lancet* 2016; Aug 27; 388(10047): 906–918
79. De Rosa G, Testa A, Maussier ML, et al. A slightly suppressive dose of l-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre. *Horm Metab Res* 1995; 27:503-7.
80. Delvecchio M, Salerno M, Vigone MC, et al. Levothyroxine requirement in congenital hypothyroidism: a 12-year longitudinal study. *Endocrine* 2015; 50(3):674-80.
81. Devereaux D, Tewelde SZ. Hyperthyroidism and thyrotoxicosis. *Emerg Med Clin North Am.* 2014;32:277–92.
82. Di Fulvio M, Coleoni AH, Pellizas CG, et al. Tri-iodothyronine induces proliferation in cultured bovine thyroid cells: evidence for the involvement of epidermal growth factor-associated tyrosine kinase activity. *J Endocrinol* 2000; 166(1):173-82.
83. Di Girolamo G, Keller GA, de Los Santos AR, et al. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. *Clin Ther* 2008; 30(11):2015-23.
84. Dietrich JW, Gieselbrecht K, Holl RW, et al. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. *Horm Metab Res* 2006; 38(1):57-9.
85. Dimitropoulos A, Molinari L, Etter K, et al. Children with congenital hypothyroidism: long-term intellectual outcome after early high-dose treatment. *Pediatr Res* 2009; 65(2):242-8.
86. Dollery C, editor. *Therapeutic Drugs - Drug monograph: Levothyroxine (sodium)*. 2nd ed. Edinburgh (UK): Churchill Livingstone; 1999.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

87. Drugs.com. Monograph: Levothyroxine [Internet]. Auckland (NZ): Drugsite Trust; 2017a [cited 2017 Aug 09]. Available from: <https://www.drugs.com/pro/levothyroxine.html>
88. Drugs.com. Monograph: Levothyroxine sodium [Internet]. Auckland (NZ): Drugsite Trust; 2017b [cited 2017 Aug 09]. Available from: <https://www.drugs.com/monograph/levothyroxine-sodium.html>
89. Eftekhari M, Asadollahi A, Beiki D, et al. The long term effect of levothyroxine on bone mineral density in patients with well differentiated thyroid carcinoma after treatment. *Hell J Nucl Med* 2008; 11(3):160-3.
90. El-Houni A, Younis N, Soran H, et al. Diarrhoea soon after levothyroxine replacement therapy. *QJM* 2002; 95(2):125-6.
91. EMA (European Medicines Agency). Alli. Procedural steps taken and scientific information after the authorisation [Internet]. London (UK): European Medicines Agency (EMA); 2017 [cited 2017 Sep 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000854/WC500024119.pdf
92. EMA (European Medicines Agency). Assessment report for Levothyroxine Alapis and associated names and Annex II. Scientific conclusions and grounds for refusal Procedure no.: EMEA/H/A-29/1328 (EMA/701628/2012) [Internet]. London (UK): European Medicines Agency (EMA); 14 Jan 2013a. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Levothyroxine_Alapis_29_4/WC500138883.pdf
93. EMA (European Medicines Agency). List of Union reference dates and frequency of submission of periodic safety update reports (PSURs). EMA/630645/2012 Rev.12. Patient Health Protection. [Internet]. London (UK): European Medicines Agency (EMA); 31 Oct 2013b.
94. Ernst FR, Sandulli W, Elmor R, et al. Retrospective study of patients switched from tablet formulations to a gel cap formulation of levothyroxine: results of the CONTROL switch study. *Drugs R D* 2017; 17:103-15.
95. Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G. REVIEW: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. *J Clin Endocrinol Metab* 2005a; 90(8):4946-54.
96. Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. *Ann Intern Med* 2005b; 142(6):412-24.
97. Eur. Ph. (European Pharmacopoeia) - European Pharmacopoeia 9th Edition (9.3) Online version 01/2018; incl. Arzneibuch-Kommentar (56. Aktualisierungslieferung 2017). Monograph: Levothyroxine sodium [CD-ROM]. Stuttgart / Eschborn: Wissenschaftliche Verlagsgesellschaft / Govi-Verlag - Pharmazeutischer Verlag GmbH; Strasbourg: Council of Europe; 2017.
98. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. *Eur J Endocrinol* 1994; 130:350-6.
99. Fatourechi V. Subclinical hypothyroidism: an update for primary care physicians. *Mayo Clin Proc* 2009; 84(1):65-71.
100. Feldt-Rasmussen U. Treatment of hypothyroidism in elderly patients and in patients with cardiac disease. *Thyroid* 2007; 17(7):619-24.
101. Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose metabolism and bioavailability of levothyroxine in the treatment of hypothyroidism; role of triiodothyronine in pituitary feedback in humans. *N Engl J Med* 1987; 316:764-70.
102. Fisher DA. Clinical review 19: Management of congenital hypothyroidism. *J Clin Endocrinol Metab* 1991; 72:523-9.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

103. Fogelfeld L, Wiviott MB, Freedman ES, et al. Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions. *N Engl J Med* 1989; 320:835-40.
104. Foley TP Jr. Hypothyroidism. *Pediatr Rev* 2004; 25(3):94-100.
105. Fonseca J, Brown R, Hochhauser D, Ginsburg J, Havard CWH. Acute adrenal crisis precipitated by thyroxine. *Br Med J (Clin Res Ed)* 1986;292:1595.
106. Forfar JC, Wathen CG, Todd WT, et al. Left ventricular performance in subclinical hypothyroidism. *Q J Med* 1985; 57:857-65.
107. Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2015; 25(7):716-59.
108. Franklyn JA. Hypothyroidism. *Med Int* 1993; 5:161-4.
109. Fujiyama K, Kiriya T, Ito M, et al. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. *Thyroid* 1995; 5:13-7.
110. Gaertner R, Reincke M. Substitution von Schilddruesenhormonen [Substitution of thyroid hormones]. *Internist (Berl)* 2008; 49(5):538, 540-4.
111. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Thyroid* 2012; 22(12):1200-35.
112. Garwood CL, Van Schepen KA, McDonough RP, et al. Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene. *Pharmacotherapy* 2006; 26(6):881-5.
113. Gharib H, James EM, Carboneau JQ, et al. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clin study. *N Engl J Med* 1987; 317:70-5.
114. Gharib H, Papini E, Garber JR, et al; AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules--2016 Update. *Endocr Pract* 2016; 22 Suppl 1:1-60.
115. Gilbert RM, Hadlow NC, Walsh JP, et al. Assessment of thyroid function during pregnancy: first-trimester (weeks 9-13) reference intervals derived from Western Australian women. *Med J Aust* 2008; 189(5):250-3.
116. Golightly LK, et al. Clinical effects of accidental levothyroxine ingestion in children. *Am J Dis Child* 1987; 141: 1025-7
117. Graves L, 3rd, Klein RM, Walling AD. Addisonian crisis precipitated by thyroxine therapy: A complication of type 2 autoimmune polyglandular syndrome. *South Med J.* 2003;96:824-7
118. Greco DS, Rosychuk RA, Ogilvie GK, et al. The effect of levothyroxine treatment on resting energy expenditure of hypothyroid dogs. *J Vet Intern Med* 1998; 12(1):7-10.
119. Grunfeld R, Kunselman A, Bustillo J, et al. Wound complications in thyroxine-supplemented patients following foot and ankle surgery. *Foot Ankle Int* 2011; 32(1):38-46.
120. Guarnieri GF, Laforgia N, Mautone A, et al. Delayed closure of ductus arteriosus in term newborns with congenital hypothyroidism: effect of L-thyroxine therapy. *Pediatr Cardiol* 2008; 29(2):455-6.
121. Guellue S, Guerses MA, Baskal N, et al. Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. *Endocr J* 1999; 46(1):221-6.
122. Guille JT, Opoku-Boateng A, Thibeault SL, et al. Evaluation and management of the pediatric thyroid nodule. *Oncologist* 2015; 20(1):19-27.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

123. Gyulai L, Bauer M, Garcia-Espana F, et al. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. *J Affect Disord* 2001; 66(2-3):185-91.
124. Hack JB, Leviss JA, Nelson LS, et al. Severe symptoms following a massive intentional L-thyroxine ingestion. *Vet Hum Toxicol* 1999; 41:323-6.
125. Hadji P, Hars O, Sturm G, et al. The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women. *Eur J Endocrinol* 2000; 142(5):445-50.
126. Hallengren B, Lantz M, Andreasson B, et al. Pregnant women on thyroxine substitution are often dysregulated in early pregnancy. *Thyroid* 2009; 19(4):391-4.
127. Hannon MJ, Behan LA, Agha A. Thyrotoxic periodic paralysis due to excessive L-thyroxine replacement in a Caucasian man. *Ann Clin Biochem* 2009; 46 (Pt 5):423-5.
128. Hansen JM, Kampmann J, Madsen SN, et al. L-thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic determination of thyroid volume. *Clin Endocrinol* 1979; 10:1-6.
129. Hashizume K, Ighikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves' disease. *N Engl J Med* 1991; 324:947-53.
130. Hegedues L, Hansen JM, Veiergang D, et al. Does prophylactic thyroxine treatment after operation for non-toxic goitre influence thyroid size? *Br Med J* 1987; 294:801-3.
131. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* 2004; 140(2):128-41.
132. Hennessey JV, Evalul JE, Tseng YC, et al. L-Thyroxine dosage: a reevaluation of therapy with contemporary preparations. *Ann Intern Med* 1986; 105:11-5.
133. Hernandez A, Obregon MJ. Triiodothyronine amplifies the adrenergic stimulation of uncoupling protein expression in rat brown adipocytes. *Am J Physiol Endocrinol Metab* 2000; 278(5):E769-77.
134. Herrmann J, Hilger P, Rusch HJ, et al. Plasmapherese in der Behandlung der thyreotoxischen Krise. *Dtsch Med Wochenschr* 1974; 99:888-92.
135. Hintze G, Emrich D, Koeberling J. Therapy of endemic goitre: controlled study on the effect of iodine and thyroxine. *Horm Metab Res* 1985; 17:362-5.
136. Hintze G, Emrich D, Koeberling J. Treatment of endemic goitre due to iodine deficiency with iodine, levothyroxine or both: results of a multicentre trial. *Eur J Clin Invest* 1989; 19:527-34.
137. Hoeffken BR, Koedding R, Hehrmann R, et al. Further results on the subcellular conversion of T₄ to T₃ and rT₃. In: Von zur Muehlen A, Schleusener H, editors. *Biochemical basis of thyroid stimulation and thyroid hormone action. Workshop Conference September 1975, Celle. Stuttgart (DE): Georg Thieme Publishers; 1976. p. 204-14.*
138. Hoffman DA, McConahay WM, Brinton LA, et al. Breast cancer in hypothyroid women using thyroid supplements. *JAMA* 1984; 251:616-9.
139. IBSA-IT. Fachinformation (SPC): Tirosint 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg Weichkapseln. Lodi (IT): IBSA Farmaceutici Italia Srl; 2012 Jan [cited 2017 Aug 01].
140. Iihara N, Kurosaki Y, Takada M, et al. Risk of hypoglycemia associated with thyroid agents is increased in patients with liver impairment. *Int J Clin Pharmacol Ther* 2008; 46(1):1-13.
141. Imada M, Kurosumi M, Fujita H. Three-dimensional imaging of blood vessels in thyroids from normal and levothyroxine sodium-treated rats. *Arch Histol Jpn* 1986; 49(3):359-67.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

142. Iranmanesh A, Lizarralde G, Johnson ML, Veldhuis JD. Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothyroidism assessed before and after partial thyroid hormone replacement. *J Clin Endocrinol Metab.* 1990;70:155–61
143. Jaggy A, Glaus T Jr, Tipold A. Neurologische Ausfallserscheinungen im Zusammenhang mit Hypothyreose beim Hund: Literaturuebersicht und Fallbeschreibungen. *Schweiz Arch Tierheilkd* 1994; 136(8):257-64.
144. Jauk B, Mikosch P, Gallowitsch HJ, et al. Unusual malabsorption of levothyroxine. *Thyroid* 2000; 10(1):93-5.
145. Jayakumar RV. Hypothyroidism. *J Indian Med Assoc* 2006; 104(10):557-60, 562.
146. Jodar E, Begona Lopez M, Garcia L, et al. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. *Osteoporos Int* 1998; 8(4):311-6.
147. Joffe RT, Brimacombe M, Levitt AJ, et al. Treatment of clinical hypothyroidism with thyroxine and triiodothyronine: a literature review and metaanalysis. *Psychosomatics* 2007; 48(5):379-84.
148. John-Kalarickal J, Pearlman G, Carlson HE. New medications which decrease levothyroxine absorption. *Thyroid* 2007; 17(8):763-5.
149. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. *Thyroid* 2014; 24(12):1670-751.
150. Jungermann K, Moehler H, editors. *Biochemie - Ein Lehrbuch fuer Studierende der Medizin, Biologie und Pharmazie. Thyroxin.* Berlin (DE): Springer-Verlag; 1980. p. 566-8.
151. Kallee E, Wahl R, Secker KH, et al. Thyreotoxische Krisen: Symptomatik und Therapie. *Med Klin* 1973; 68:1689-96.
152. Kapdi CC, Wolfe JN. Breast cancer: relationship to thyroid supplements for hypothyroidism. *JAMA* 1976; 236:1124-27.
153. Kaur, S., Bhalla, M., Thami, G.P. Subacute lichenoid eruption due to L-thyroxine overdose. *Dermatology.* 2003;206:346–347
154. Kehar M. Approach to goiter in children. In: Sachdeva A, Dutta AK, editors. *Advances in pediatrics.* 2nd ed. New Delhi (IN): Jaypee Brothers Medical Publishers (P) Ltd.; 2012. p. 1254-8.
155. Kempers MJ, Vulsma T, Wiedijk BM, et al. The effect of life-long thyroxine treatment and physical activity on bone mineral density in young adult women with congenital hypothyroidism. *J Pediatr Endocrinol Metab* 2006; 19(12):1405-12.
156. Kisch E, Segall HS. Interaction between simvastatin and L-thyroxine. *Ann Intern Med* 2005; 143(7):547.
157. Koc M, Ersoz HO, Akpınar I, et al. Effect of low- and high-dose levothyroxine on thyroid nodule volume: a crossover placebo-controlled trial. *Clin Endocrinol (Oxf)* 2002; 57(5):621-8.
158. Koehle J. Biochemistry of Iodothyronine deiodination. *Acta Austriaca (Special edition)* 1988; 15:22-4.
159. Kohno A, Hara Y. Severe myocardial ischemia following hormone replacement in two cases of hypothyroidism with normal coronary arteriogram. *Endocr J* 2001; 48(5):565-72.
160. Kondziella D, Brederlau A, Asztely F. Choreathetosis due to abuse of levothyroxine. *J Neurol*, 2009; 256:2106
161. Kuemmerle HP, Hitzenberger G, Spitzky KH, editors. *Klinische Pharmakologie. Levo-Thyroxin-Natrium, T4 / Liothyronin, T3.* 4.Aufl./53. Erg.-Lfg. 11/1997. Landsberg/Muenchen (DE): Ecomed Verlagsgesellschaft; 1984; inkl. 53. Erg.-Lfg. 1997.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

162. Kulacoglu H, Dener C, Ziraman I, et al. Thyroxine prophylaxis after bilateral subtotal thyroidectomy for multinodular goiter. *Endocr J* 2000; 47(3):349-52.
163. Kulig K, et al. Levothyroxine overdosage associated with seizures in a young child. *JAMA* 1985 254: 2109–10.
164. Kyriazopoulou V, Michalaki M, Georgopoulos N, et al. Recommendations for thyroxin therapy during pregnancy. *Expert Opin Pharmacother* 2008; 9(3):421-7.
165. La Vignera S, Vicari E, Tumino S, et al. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history. *Minerva Ginecol* 2008; 60(6):475-84.
166. LaFranchi S. Diagnosis and treatment of hypothyroidism in children. *Compr Ther* 1987; 13(10):20-30.
167. Larijani B, Gharibdoost F, Pajouhi M, et al. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women. *J Clin Pharm Ther* 2004; 29(1):1-5.
168. Larsen PR, DeRubertis F, Yamashita K, et al. In vitro demonstration of iodine-trapping defect but normal thyrotropin (TSH) responsiveness in benign and malignant "cold" thyroid nodules. *Trans Assoc Am Phys* 1972; 85:309-16.
169. Lazarus J, Brown RS, Daumerie C, et al. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. *Eur Thyroid J* 2014; 3(2):76-94.
170. Lazarus JH. Thyroid hormone and intellectual development: a clinician's view. *Thyroid* 1999; 9(7):659-60.
171. Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. *J Clin Endocrinol Metab* 1996; 81(2):857-9.
172. Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. *Br J Clin Pharmacol* 2005; 60(3):337-41.
173. Livadariu E, Valdes-Socin H, Burlacu MC, et al. Pseudomalabsorption of thyroid hormones: case report and review of the literature. *Ann Endocrinol (Paris)* 2007; 68(6):460-3.
174. Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. *Best Pract Res Clin Endocrinol Metab* 2009; 23(6):781-92.
175. Lomenick JP, El-Sayyid M, Smith WJ. Effect of levo-thyroxine treatment on weight and body mass index in children with acquired hypothyroidism. *J Pediatr* 2008; 152(1):96-100.
176. Lomenick JP, Wang L, Ampah SB, et al. Generic levothyroxine compared with synthroid in young children with congenital hypothyroidism. *J Clin Endocrinol Metab* 2013; 98(2):653-8.
177. Lossius MI, Taubøll E, Mowinckel P, Gjerstad L. Reversible effects of antiepileptic drugs on thyroid hormones in men and women with epilepsy: A prospective randomized double-blind withdrawal study. *Epilep & Behav* 2009; 16 (1):64-68
178. Mainenti MR, Vigario PS, Teixeira PF, et al. Effect of levothyroxine replacement on exercise performance in subclinical hypothyroidism. *J Endocrinol Invest* 2009; 32(5):470-3.
179. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. *Ann Intern Med* 1993; 119:492-502.
180. Mao S, Wang Y, Jiang G, et al. Effects of levothyroxine therapy on left and right ventricular function in neonates with congenital hypothyroidism: a tissue Doppler echocardiography study. *Eur J Pediatr* 2007; 166(12):1261-5.
181. Marchant B, Lees JF, Alexander WD. Antithyroid drugs. In: Hershman JM, Bray HG, eds. *The Thyroid Physiology and Treatment of Disease*. Oxford (UK): Pergamon Press; 1979. p. 209-52.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

182. Marcocci C, Golia F, Bruno-Bosio G, et al. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. *J Clin Endocrinol Metab* 1994; 78:818-23.
183. Martindale - The Complete Drug Reference. Levothyroxine sodium / Thyroid and antithyroid drugs [Internet]. London (UK): Pharmaceutical Press; 2017 [cited 2017 Aug 09]. Available from: <https://www.medicinescomplete.com>
184. Matusik P, Malecka-Tendera E, Franek E, et al. Bone mineral density and metabolism in levothyroxine-treated adolescent girls with euthyroid diffuse goiter. *Endokrynol Pol* 2010; 61(1):14-9.
185. Mazokopakis EE, Starakis IK, Papadomanolaki MG, et al. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy. *Curr Med Res Opin* 2006; 22(7):1369-73.
186. Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. *Semin Oncol* 1987; 14:315-32.
187. McElduff A. Measurement of free thyroxine (T4) levels in pregnancy. *Aust N Z J Obstet Gynaecol* 1999; 39(2):158-61.
188. McIver B, Rae P, Beckett G, et al. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. *N Engl J Med* 1996; 334:220-4.
189. Meng W, editor. *Schildruesenerkrankungen. Anatomie und Physiologie*. 3rd ed. Jena (DE): Gustav Fischer Verlag; 1992a. p. 18-26.
190. Meng W, editor. *Schildruesenerkrankungen. Erworbene Hypothyreose*. 3rd ed. Jena (DE): Gustav Fischer Verlag; 1992b. p. 227-33.
191. Meng W, editor. *Schildruesenerkrankungen. Therapie der primären Hypothyreose im Erwachsenenalter*. 3rd ed. Jena (DE): Gustav Fischer Verlag; 1992c. p. 244-51.
192. Merck Index – The Merck Index. Thyroxine [CD-ROM]. 14th ed. Whitehouse Station (NJ): Merck & Co., Inc. 2006 [cited 2017 Sep 20].
193. Merck-GR. Summary of Product Characteristics: Euthyrox 50 microgram tablets and Euthyrox 100 microgram tablets [Internet]. Athens (GR): Merck A.E. Hellas; 2015 Aug 03 [cited 2017 Oct 05]. Available from: http://www.papaloizou.com/PublicDocsPDF/SPCs/Euthyrox_SPC.pdf
194. Merck-NL. Summary of Product Characteristics: Euthyrox 25/50/75/88/100/112/125/137/150/175/200, tabletten 25/50/75/88/100/112/125/137/150/175/200 microgram [Internet]. Schiphol-Rijk (NL): Merck BV; 2015 May 12 [cited 2017 Oct 05]. Available from: <https://db.cbg-meb.nl/IB-teksten/h09009.pdf>
195. Merck-Sante-F (2016) Summary of Product Characteristics: LEVOTHYROX 100 microgrammes, comprimé sécable. [Internet]. LYON (F): Merck Sante; 2016 Sep 26 [cited 2017 Oct 30]
196. Merck-Serono-DE. Summary of Product Characteristics: Euthyrox® 25 Mikrogramm Tabletten / Euthyrox® 50 Mikrogramm Tabletten / Euthyrox® 75 Mikrogramm Tabletten / Euthyrox® 88 Mikrogramm Tabletten / Euthyrox® 100 Mikrogramm Tabletten / Euthyrox® 112 Mikrogramm Tabletten / Euthyrox® 125 Mikrogramm Tabletten / Euthyrox® 137 Mikrogramm Tabletten / Euthyrox® 150 Mikrogramm Tabletten / Euthyrox® 175 Mikrogramm Tabletten / Euthyrox® 200 Mikrogramm Tabletten. [Internet]. Darmstadt (DE): Merck Serono GmbH; 2016 Aug.
197. Mercurio G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. *J Clin Endocrinol Metab* 2000; 85(1):159-64.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

198. Mercury-UK. Summary of Product Characteristics: Eltroxin 100mcg tablets [Internet]. London (UK): Mercury Pharmaceuticals Ltd; 2016 Apr 20 [cited 2017 Aug 15]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=23699>
199. Mercury-UK. Summary of Product Characteristics: Eltroxin 50 micrograms per 5 ml oral solution [Internet]. London (UK): Mercury Pharmaceuticals Ltd.; 2013 Aug 30 [cited 2017 Aug 15]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=26563>
200. Mercury-UK. Summary of Product Characteristics: Levothyroxine 100micrograms per 5ml Oral Solution [Internet]. London (UK): Mercury Pharmaceuticals Ltd; 2015 May 15 [cited 2017 Aug 01]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=28153>
201. Mersebach H, Rasmussen AK, Kirkegaard L, et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. *Pharmacol Toxicol* 1999; 84(3):107-9.
202. MHRA (Medicines and Healthcare products Regulatory Agency). Levothyroxine tablet products: a review of clinical & quality considerations [Internet]. London (UK): Medicines and Healthcare Products Regulatory Agency (MHRA); 07 Jan 2013b. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/420997/CHM_Review_for_MHRA_website_Levothyroxine_sodium_FINAL_04_Jan_2013.pdf
203. MHRA (Medicines and Healthcare products Regulatory Agency). UK Public Assessment Report: Evotrox 25 mcg, 50 mcg, 100 mcg/5ml oral solution (PL 20249/0004, PL 20249/0007, PL 20249/0005) [Internet]. Wembley (UK): Kappin Limited; 23 Jan 2013a. Available from: <http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2024367.pdf>
204. Michalaki MA, Gkotsina MI, Mamali I, et al. Impaired pharmacokinetics of levothyroxine in severely obese volunteers. *Thyroid* 2011; 21(5):477-81.
205. Mikosch P, Jauk B, Gallowitsch HJ, et al. Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism. *Thyroid* 2001; 11(3):257-63.
206. Moericke R, Tittbach O, Kellner K, et al. Der Einfluß der noradrenergen Stimulation auf die peripheren venösen Thyroxin- und Liothyroninkonzentrationen stoffwechselgesunder jugendlicher Probanden. *Z Gesamte Inn Med* 1980; 35(10):433-9.
207. Moeschlin S, editor. *Klinik und Therapie der Vergiftungen*. 7th ed. Stuttgart (DE): Georg Thieme Verlag; 1986. p. 522-4.
208. Morita T, Tamai H, Oshima A, et al. Changes in serum thyroid hormone, thyrotropin and thyroglobulin concentrations during thyroxine therapy in patients with solitary thyroid nodules. *J Clin Endocrinol Metab* 1989; 69:227-30.
209. Munoz-Torres M, Varsavsky M, Alonso G. Lactose intolerance revealed by severe resistance to treatment with levothyroxine. *Thyroid* 2006; 16(11):1171-3.
210. Murray JS, Jayarajasingh R, Perros P. Lesson of the week: Deterioration of symptoms after start of thyroid hormone replacement. *BMJ*. 2001;323:332-3
211. Ng SM, Anand D, Weindling AM. High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism. *Cochrane Database of Systematic Reviews* 2009, Issue 1. Art. No.: CD006972. DOI: 10.1002/14651858.CD006972.pub2.
212. Nikfar S, Koren G. Managing hypothyroidism during pregnancy. *Can Fam Physician* 2001; 47:1555-6.
213. Nolan SR, Self TH, Norwood JM. Interaction between rifampin and levothyroxine. *South Med J* 1999; 92(5):529-31.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

214. Nomura S, Ikegami H, Wada H, et al. Role of levothyroxine supplementation in extremely low birth weight infants who have transient hypothyroidism without thyroid-stimulating hormone elevation. *Osaka City Med J* 2014; 60(1):29-37. Only abstract available.
215. Nugent, J.S., Nugent, A.L., Whisman, B.A., White, K., Hagan, L.L. Levothyroxine anaphylaxis? Vocal cord dysfunction mimicking an anaphylactic drug reaction. *Ann Allergy Asthma Immunol.* 2003;91:337–341
216. Oe K, Yamagata T, Mori K. Acute myocardial infarction following hormone replacement in hypothyroidism. *Int Heart J* 2007; 48(1):107-11.
217. Oerbeck B, Reinvang I, Sundet K, et al. Young adults with severe congenital hypothyroidism: cognitive event related potentials (ERPs) and the significance of an early start of thyroxine treatment. *Scand J Psychol* 2007; 48(1):61-7.
218. Ogilvy-Stuart AL. Neonatal thyroid disorders. *Arch Dis Child Fetal Neonatal Ed* 2002; 87(3):F165-71.
219. Ohmori M, Harada K, Tsuruoka S, et al. Levothyroxine-induced liver dysfunction in a primary hypothyroid patient. *Endocr J* 1999; 46(4):579-83.
220. Olbricht T, Hoff HG, Benker G, et al. Sonographische Volumetrie der Schilddruese zur Verlaufskontrolle bei einer Thyroxin- und Jodidbehandlung der blanden Struma. *Dtsch Med Wochenschr* 1985; 110:863-6.
221. Opazo MC, Gianini A, Pancetti F, et al. Maternal hypothyroxinemia impairs spatial learning and synaptic nature and function in the offspring. *Endocrinology* 2008; 149(10):5097-106. Erratum in: *Endocrinology* 2009; 150(1):556.
222. Osborn DA. Thyroid hormones for preventing neurodevelopmental impairment in preterm infants (Cochrane review). In: *The Cochrane Library*, Issue 2, 2003. Oxford Update Software.
223. Osterode W, Zettinig G, Poetzi C, et al. Increased lead excretion in hypothyroid patients after levothyroxine medication. *J Toxicol Environ Health A* 2002; 65(9):649-54.
224. Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. *Eur J Pharm Biopharm* 2009; 72(1):105-10.
225. Panza N, Biondi B, Carella C, et al. About thyroxine administration during lithium therapy. *J Endocrinol Invest* 1999; 22(10):820-1.
226. Papini E, Petrucci L, Guglielmi R, et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. *J Clin Endocrinol Metab* 1998; 83(3):780-3.
227. Parle J, Roberts L, Wilson S, et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: The Birmingham Elderly Thyroid study. *J Clin Endocrinol Metab* 2010; 95(8):3623-32.
228. Patane S, Marte F. Acute myocardial infarction during L-thyroxine therapy in a patient with intermittent changing axis deviation, permanent atrial fibrillation and without significant coronary stenoses. *Int J Cardiol* 2010; 138(1):e8-11.
229. PDR (Physicians´ Desk Reference). Levoxyl (levothyroxine sodium) [Internet]. 2017a [cited 2017 Sep 20]. Available from: <http://www.pdr.net/drug-summary/Levoxyl-levothyroxine-sodium-2553.73>
230. PDR (Physicians´ Desk Reference). Synthroid® (levothyroxine sodium tablets, USP) [Internet]. 2017b [cited 2017 Sep 20]. Available from: <http://www.pdr.net/drug-information/synthroid?druglabelid=26>

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

231. PDWS. Rapporteur's public assessment report for paediatric studies submitted in accordance with article 45 of regulation (EC) No1901/2006, as amended. Levothyroxine (l-thyroxine) SE/W/004/pdWS/001. 2010 Apr 23.
232. Peleg RK, Efrati S, Benbassat C, et al. The effect of levothyroxine on arterial stiffness and lipid profile in patients with subclinical hypothyroidism. *Thyroid* 2008; 18(8):825-30.
233. Perlsteyn M, Deladoey J, Van Vliet G. Similar age-dependent levothyroxine requirements of schoolchildren with congenital or acquired hypothyroidism. *Eur J Pediatr* 2016; 175(6):869-72.
234. Peroni E, Vigone MC, Mora S, et al. Congenital hypothyroidism treatment in infants: a comparative study between liquid and tablet formulations of levothyroxine. *Horm Res Paediatr* 2014; 81(1):50-4.
235. Pfannenstiel P, Saller B. *Schilddruesenkrankheiten - Diagnose und Therapie*. 2nd ed. Henning Berlin, editor. Berlin (DE): Berliner Medizinische Verlagsanstalt GmbH; 1991a. p. 28-33.
236. Pfannenstiel P, Saller B. *Schilddruesenkrankheiten - Diagnose und Therapie*. 2nd ed. Henning Berlin, editor. Berlin (DE): Berliner Medizinische Verlagsanstalt GmbH; 1991b. p. 79-89.
237. Pickardt CR, Grueters-Kießlich A, Grußendorf M, et al. Schilddrüse. In: Deutsche Gesellschaft fuer Endokrinologie, editor. *Rationelle Diagnostik in der Endokrinologie einschließlich Diabetologie und Stoffwechsel*. Stuttgart (DE): Georg Thieme Verlag; 1993. p. 42, 52-5.
238. Pincus D, Gomes T, Hellings C, et al. A population-based assessment of the drug interaction between levothyroxine and warfarin. *Clin Pharmacol Ther* 2012; 92(6):766-70.
239. Pop VJ, Kuijpers JL, Van Baar AL, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. *Clin Endocrinol (Oxf)* 1999; 50(2):149-55.
240. Quan ML, Pasioka JL, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. *J Surg Oncol* 2002; 79(1):62-9.
241. ratiopharm-DE. Fachinformation (SPC): Levothyroxin-ratiopharm 25, 50, 100 Mikrogramm/5 ml Loesung zum Einnehmen [Internet]. Ulm (DE): ratiopharm GmbH; 2017 May [cited 2017 Aug 01]. Available from: <https://portal.dimdi.de/amispb/doc/2017/06/16/2183359/O1d18e95c22144b298805109f046fd2c8.pdf>
242. Reddy SS. Endocrinology update 2006. *Cleveland Clin J Med* 2006; 73(11):1019-24.
243. Regalbuto C, Maiorana R, Alagona C, et al. Effects of either LT4 monotherapy or LT4/LT3 combined therapy in patients totally thyroidectomized for thyroid cancer. *Thyroid* 2007; 17(4):323-31.
244. Reiners C. Vorsicht beim Austausch von Levothyroxin. *Dtsch Apoth Z* 2008; 148(14):65-8.
245. Reverter J, Lucas A, Salinas I, et al. Suppressive therapy with levothyroxine for solitary thyroid nodules. *Clin Endocrinol* 1992; 36:25-8.
246. Rivkees SA, Bode HH, Crawford JD. Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature. *N Engl J Med* 1988; 318(10):599-602.
247. Rogers DG. Thyroid disease in children. *Am Fam Physician* 1994; 50(2):344-50.
248. Rosenthal MJ, Hunt WC, Garry PJ, et al. Thyroid failure in the elderly. Microsomal antibodies as discriminant for therapy. *JAMA* 1987; 258:209-13.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

249. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid* 2016; 26(10):1343-1421.
250. Ross DS. Long-term management of differentiated thyroid cancer. *Endocrinol Metab Clin North Am* 1990; 19:719-39.
251. Rossoff IS, editor. *Encyclopedia of clinical toxicology - Thyroxine*. Boca Raton (FL): The Parthenon Publishing Group; 2002. p. 1063-4.
252. Roti E, Minelli R, Gardini E, et al. The use and misuse of thyroid hormones. *Endoc Rev* 1993; 4:401-23.
253. Rovet JF, Daneman D, Bailey JD. Psychologic and psychoeducational consequences of thyroxine therapy for juvenile acquired hypothyroidism. *J Pediatr* 1993; 122(4):543-9.
254. Rudas S, Schmitz M, Pichler P, et al. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine. *Biol Psychiatry* 1999; 45(2):229-33.
255. Ryan DP, da Silva MR, Soong TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. *Cell*. 2010;140:88–98
256. Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. *Endocr Pract* 2007; 13(4):345-9.
257. Salerno M, Lettierio T, Esposito-del Puente A, et al. Effect of long-term L-thyroxine treatment on bone mineral density in young adults with congenital hypothyroidism. *Eur J Endocrinol* 2004; 151(6):689-94.
258. Salerno M, Oliviero U, Lettierio T, et al. Long-term cardiovascular effects of levothyroxine therapy in young adults with congenital hypothyroidism. *J Clin Endocrinol Metab* 2008; 93(7):2486-91.
259. Santaguida MG, Virili C, Del Duca SC, et al. Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. *Endocrine* 2015; 49(1):51-7.
260. Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. *J Clin Endocrinol Metab* 2005; 90(1):124-7.
261. Schicha H, Schober O, editors. *Nuklearmedizin - Basiswissen und klinische Anwendung*. 4th ed. Stuttgart (DE): Schattauer Verlag; 2000. p. 107-13.
262. Schifferdecker E, Jungmann E, Ruemelin A, et al. Behandlung mit Dopamin - eine wichtige Größe bei der Beurteilung der Schilddrüsenfunktion kritisch Kranker. *Klin Wochenschr* 1985; 63 Suppl 4:71-2.
263. Schneider R, Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. *Exp Clin Endocrinol Diabetes* 2003; 111(8):455-70.
264. Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. *JAMA* 1998; 279(10):750.
265. Schroeder BM. ACOG (American College of Obstetricians and Gynecologists) practice bulletin on thyroid disease in pregnancy. *Am Fam Physician* 2002; 65(10):2158, 2161-2.
266. Schumm PM, Usadel KH, Althoff PH, et al. Strumalangezeittherapie mit Thyroxin und Jodid. *Inn Med* 1983; 10:203-7.
267. Schwabe U, Paffrath D, editors. *Arzneiverordnungsreport 2015 - Aktuelle Daten, Kosten, Trends und Kommentare*. Berlin (DE): Springer-Verlag; 2015. p. 6-7; 999-1002.
268. Seidel CH, Sydow K, Ziegelitz D, et al. Schilddrüsenhormone, Thyrotropin, TBG-Spiegel und Bindungskapazität. *Dtsch Gesundheitsw* 1980; 35(12):460-6.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

269. Selva KA, Harper A, Downs A, et al. Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH. *J Pediatr* 2005; 147(6):775-80.
270. Selva KA, Mandel SH, Rien L, et al. Initial treatment dose of L-thyroxine in congenital hypothyroidism. *J Pediatr* 2002; 141(6):786-92.
271. Seo MK, Yoon JS, So CH, et al. Intellectual development in preschool children with early treated congenital hypothyroidism. *Ann Pediatr Endocrinol Metab* 2017; 22(2):102-7.
272. Serb-FR. L-thyroxine Serb 150 microgrammes/ml, solution buvable en gouttes [Internet]. Paris (FR): SERB; 2015 Jul 21 [cited 2017 Aug 29]. Available from: <http://www.medisite.fr/dictionnaire-des-medicaments-l-thyroxine-serb-150-microgrammesml-solution-buvable-en-gouttes.604850.8028.html>
273. Shakir KM, Turton D, Aprill BS, et al. Anemia: a cause of intolerance to thyroxine sodium. *Mayo Clin Proc* 2000; 75(2):189-92.
274. Sheppard MC, Holder R, Franklyn JA. Levothyroxine treatment and occurrence of fracture of the hip. *Arch Intern Med* 2002; 162(3):338-43.
275. Shibata, H., Hayakawa, H., Hirukawa, M., Tadokoro, K., Ogata, E. Hypersensitivity caused by synthetic thyroid hormones in hypothyroid patient with Hashimoto's thyroiditis. *Arch Intern Med*. 1986; 146:1624–1652.
276. Shilo L, Kovatz S, Hadari R, et al. Massive thyroid hormone overdose: kinetics, clinical manifestations and management. *Isr Med Assoc J* 2002; 4(4):298-9.
277. Shinno H, Inami Y, Inagaki T, et al. Successful treatment with levothyroxine for idiopathic hypersomnia patients with subclinical hypothyroidism. *Gen Hosp Psychiatry* 2009; 31(2):190-3.
278. Siegenthaler W, editor. *Klinische Pathophysiologie (Schilddruese)*. 7th ed. Stuttgart (DE): Georg Thieme Verlag; 1994. p. 263-78.
279. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. *JAMA* 1995; 273(10):808-12.
280. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. *JAMA* 2000; 283(21):2822-5.
281. Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. *Thyroid* 2001; 11(10):967-71.
282. Singh R. Determinants of levothyroxine dose required to achieve euthyroidism in pediatric population-a hospital-based prospective follow-up study. *Eur J Pediatr* 2017; 176(8):1027-33.
283. Smit BJ, Kok JH, De Vries LS, et al. Somatosensory evoked potentials in very preterm infants in relation to L-thyroxine supplementation. *Pediatrics* 1998; 101(5):865-9.
284. Stockigt JA. Thyroid disease. *Med J Aust* 1993; 158:770-4.
285. Studer H, Gerber H. Clinical manifestations and management of nontoxic diffuse and nodular goitre. In: Braverman LE, Utiger HR, editors. *The Thyroid. A Fundamental and Clinical text*. 6th ed. Philadelphia (PA): JB Lippincott; 1991. p. 1114-8.
286. Svensson J, Ericsson UB, Nilsson P, et al. Levothyroxine treatment reduces thyroid size in children and adolescents with chronic autoimmune thyroiditis. *J Clin Endocrinol Metab* 2006; 91(5):1729-34.
287. Tamai H, Hayaki I, Kawai K, et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. *J Clin Endocrinol Metab* 1995; 80:1481-4.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

288. Teixeira PF, Reuters VS, Ferreira MM, et al. Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial. *Horm Metab Res* 2008; 40(1):50-5.
289. Teva-NL. Summary of Product Characteristics: Levothyroxinenatrium 25, 50, 100 microgram/5ml TEVA. Haarlem (NL): Teva Nederland BV. Date: 10 Jan 2013.
290. Thangaratinam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. *BMJ* 2011; 342:d2616.
291. Tseng A, Fletcher D. Interaction between ritonavir and levothyroxine. *AIDS* 1998; 12(16):2235-6.
292. Tunbridge WM, Brewis M, French JM, et al. Natural history of autoimmune thyroiditis. *Br Med J (Clin Res Ed)* 1981; 282:258-62.
293. Unal O, Erturk E, Ozkan H, et al. Effect of levothyroxine treatment on QT dispersion in patients with subclinical hypothyroidism. *Endocr Pract* 2007; 13(7):711-5.
294. Upadhyaya L, Agrawal JK, Dubey GP. Effect of L-thyroxine and carbimazole on blood levels of biogenic amines in rat. *Exp Clin Endocrinol* 1993; 101(5):307-10.
295. Upala S, Young WC, Sanguaneko A. Primary Adrenal Insufficiency Misdiagnosed as Hypothyroidism in a Patient with Polyglandular Syndrome. *N Am J Med Sci.* 2016 May; 8(5): 226–228.
296. Vaidya B, Pearce SHS. Diagnosis and management of thyrotoxicosis. *BMJ* 2014; 349:g5128
297. Valizadeh M, Seyyed-Majidi MR, Hajibeigloo H, et al. Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. *Endocr Res* 2009; 34(3):80-9.
298. Van Vliet G, Deladoey J. Diagnosis, treatment and outcome of congenital hypothyroidism. *Endocr Dev* 2014; 26:50-9.
299. Van Wassenaer AG, Kok JH, de Vijlder JJ, et al. Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation. *N Engl J Med* 1997; 336:21-26.
300. Van Wassenaer AG, Westera J, Houtzager BA, et al. Ten-year follow-up of children born at <30 weeks' gestational age supplemented with thyroxine in the neonatal period in a randomized, controlled trial. *Pediatrics* 2005; 116(5):e613-8.
301. Vanhole C, Aerssens P, Naulaers G, et al. L-thyroxine treatment of preterm newborns: clinical and endocrine effects. *Pediatr Res* 1997; 42(1):87-92.
302. Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: clinical challenges. *J Thyroid Res.* 2014;2014:649502
303. Villar HC, Saconato H, Valente O, et al. Thyroid hormone replacement for subclinical hypothyroidism (Cochrane Review). In: *The Cochrane Library*, 2008 Issue 1. Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
304. Virili C, Trimboli P, Romanelli F, et al. Liquid and softgel levothyroxine use in clinical practice: state of the art. *Endocrine* 2016; 54(1):3-14.
305. Vita R, Benvenga S. Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in soft gel capsule. *Endocr Pract* 2014; 20(3):e38-41.
306. Vita R, Saraceno G, Trimarchi F, et al. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. *Endocrine* 2013; 43(1):154-60.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

307. Von Heppe JH, Krude H, L'Allemand D, et al. The use of L-T4 as liquid solution improves the practicability and individualized dosage in newborns and infants with congenital hypothyroidism. *J Pediatr Endocrinol Metab* 2004; 17(7):967-74.
308. Walter-Sack I, Clanget C, Ding R, et al. Assessment of levothyroxine sodium bioavailability: recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures. *Clin Pharmacokinet* 2004; 43(14):1037-53.
309. Wasniewska M, Corrias A, Aversa T, et al. Comparative evaluation of therapy with L-thyroxine versus no treatment in children with idiopathic and mild subclinical hypothyroidism. *Horm Res Paediatr* 2012; 77(6):376-81.
310. Wemeau JL, Caron P, Schvartz C, et al. Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. *J Clin Endocrinol Metab* 2002; 87(11):4928-34.
311. Wenzel KW, Kirschsieper HE. Untersuchungen zur Resorption von L-Thyroxin beim Gesunden. *Compart N Nucl Med* 1975; 2:30-1.
312. WHO (World Health Organization). Model list of essential medicines [Internet]. Levothyroxine. 20th ed. Geneva (CH): WHO; March 2017a. [cited 2017 Aug 09]; p. 42. Available from: http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?ua=1
313. WHO (World Health Organization). WHO model list of essential medicines for children [Internet]. Levothyroxine. 6th list. Geneva (CH): WHO; March 2017b [cited 2017 Aug 09]. p. 31. Available from: http://www.who.int/medicines/publications/essentialmedicines/6th_EMLc2017.pdf?ua=1
314. Williams FL, Watson J, Ogston SA, et al. Maternal and umbilical cord levels of T4, FT4, TSH, TPOAb, and TgAb in term infants and neurodevelopmental outcome at 5.5 years. *J Clin Endocrinol Metab* 2013; 98(2):829-38.
315. Wockhardt-UK. Summary of Product Characteristics: Levothyroxine 50micrograms/5ml Oral Solution [Internet]. Wrexham (UK): Wockhardt UK Ltd; 2017 Jun 23 [cited 2017 Aug 15]. Available from: <https://www.medicines.org.uk/emc/print-document?documentId=33388>
316. Woeber KA. Update on the management of hyperthyroidism and hypothyroidism. *Arch Fam Med* 2000; 9(8):743-7.
317. Wood RW, Martis L, Gillum AW, et al. In vitro dissolution and in vivo bioavailability of commercial levothyroxine sodium tablets in the hypothyroid dog model. *J Pharm Sci* 1990; 79(2):124-7.
318. Yamanaka H, Nakajima M, Katoh M, et al. Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. *Drug Metab Dispos* 2007; 35(9):1642-8.
319. Yang RL, Zhu ZW, Zhou XL, et al. Treatment and follow-up of children with transient congenital hypothyroidism. *J Zhejiang Univ Sci B* 2005; 6(12):1206-9.
320. Yazici M, Gorgulu S, Sertbas Y, et al. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function. *Int J Cardiol* 2004; 95(2-3):135-43.
321. Yousef A, Clark J, Doi SA. Thyroxine suppression therapy for benign, non-functioning solitary thyroid nodules: a quality-effects meta-analysis. *Clin Med Res* 2010; 8(3-4):150-8.
322. Yue CS, Benvenga S, Scarsi C, et al. When bioequivalence in healthy volunteers may not translate to bioequivalence in patients: differential effects of increased gastric pH on the pharmacokinetics of levothyroxine capsules and tablets. *J Pharm Pharm Sci* 2015; 18(5):844-55.

2.5 Clinical Overview
Lévothyroxine Genevrier Soft Capsules

13 µg / 25 µg / 50 µg / 75 µg / 88 µg / 100 µg / 112 µg / 125 µg / 137 µg / 150 µg / 175 µg / 200 µg

323. Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. *Arzneimittelforschung* 2012; 62(12):631-6.
324. Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. *Thyroid* 2011; 21(5):483-6.
325. Zendzian-Piotrowska M, Gorska M, Dworakowski W, et al. Effect of triiodothyronine on phospholipid metabolism in skeletal muscles of the rat. *J Physiol Pharmacol* 2000; 51(1):103-10.